Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides

Advances in Pharmacology

Volumn 40, Issue C, 1997, Pages 1-49

  Crooke, Stanley T ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

ANIMAL; CHEMISTRY; HUMAN; REVIEW;

ANIMALS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0030623524     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60136-2     Document Type: Article

References (228)

1. Abe J., Zhou W., Taguchi J., et al. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense CDC2 and CDK2 oligonucleotides in rat carotid artery. Biochem. Biophys. Res. Commun. 198 (1994) 16
2. Adams J.U., Chen X.H., de Riel J.K., et al. In vivo treatment with antisense oligodeoxynucleotide to kappa-opioid receptors inhibited kappa-agonist-induced analgesia in rats. Regul. Pept. 54 (1994) 1
3. Agrawal S., Goodchild J., Civeira M.P., et al. Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 7079
4. Agrawal S., Temsamani J., and Tang J.Y. Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 7595
5. Agrawal S., Zhang X., Lu Z., et al. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 50 (1995) 571
6. Agris C.H., Blake K.R., Miller P.S., et al. Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoxyribonuclease methylphos-phonates. Biochemistry 25 (1986) 6268
7. Akabayashi A., Wahlestedt C., Alexander J.T., et al. Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion. Mol. Brain Res. 21 (1994) 55
8. Akino K., Ohtsuru A., Yano H., et al. Antisense inhibition of parathyroid hormone-related peptide gene expression reduces malignant pituitary tumor progression and metastases in the rat. Cancer Res. 56 (1996) 77
9. Alvarado-Urbina G., Sathe G.M., Liu W.C., et al. Automated synthesis of gene fragments. Science 214 (1981) 270
10. Amaratunga A., Morin P.J., Kosik K.S., et al. Inhibition of kinesin synthesis and rapid anterograde axonal transport in vivo by an antisense oligonucleotide. J. Biol. Chem. 268 (1993) 17427
11. 1 receptor. Regul. Pept. 59 (1995) 171
12. Azad R.F., Driver V.B., Tanaka K., et al. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemothe. 37 (1993) 1945
13. Baker B. Decapitation of a 5 capped oligoribonucleotide by ortho-phenanthroline:Cu(II). J. Am. Chem. Soc. 115 (1993) 3378
14. Baker B.F., Miraglia L., and Hagedorn C.H. Modulation of eukaryotic initiation factor-4E binding to 5′ capped oligoribonucleotides by modified antisense oligonucleotides. J. Biol. Chem. 267 (1992) 11495
15. Barrett J.C., Miller P.S., and Ts'o P.O.P. Inhibitory effect of a complex formation with oligodeoxyribonucleotide ethyl phosphotriesters on transfer ribonucleic acid aminoacylation. Biochemistry 13 (1974) 4897
16. Barton C.M., and Lemoine N.R. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br. J. Cancer 71 (1995) 429
17. Bayever E., Iversen P.L., Bishop M.R., et al. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase 1 trial. Antisense Res. Dev. 3 (1993) 383
18. Bellon L., Leydier C., Barascut J.-L., et al. 4-Thio RNA: A novel class of sugar-modified β-RNA. In: Sanghvi Y.S., and Cook P.D. (Eds). Carbohydrate Modifications in Antisense Research (1994), American Chemical Society, Washington, D.C. 68
19. Bennett C.F., and Crooke S.T. Oligonucleotide-based inhibitors of cytokine expression and function. In: Henderson B., and Bodmer M.W. (Eds). "Therapeutic Modulation of Cytokines," a volume in "Pharmacology and Toxicology: Basic and Clinical Aspects (1996), CRC Press, Boca Raton, Florida. 171-193
20. Bennett C.F., Chiang M.-Y., Chan H., et al. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41 (1992) 1023
21. Bennett C.F., Chiang M.-Y., Chan H., et al. Use of cationic lipids to enhance the biological activity of antisense oligonucleotides. J. Liposome Res. 3 (1993) 85
22. Boutorine A., Huet C., Saison T., et al. Cell penetration studies of oligonucleotides derivatized with cholesterol and porphyrins. Conf. Nucleic Acid Ther. (1991) 60 (abstr.)
23. Breslauer K.J., Frank R., Blocker H., et al. Predicting DNA duplex stability from base sequence. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 8746
24. Burch R.M., and Mahan L.C. Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice. J. Clin. Invest. 88 (1991) 1190
25. Burgess T.L., Fisher E.F., Ross S.L., et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 4051
26. Campbell J.M., Bacon T.A., and Wickström E. Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Methods 20 (1990) 259
27. Caruthers M.H. Gene synthesis machines: DNA chemistry and its uses. Science 230 (1985) 281
28. Castro-Alamancos M.A., and Torres-Aleman I. Learning of the conditioned eye-blink response is impaired by an antisense insulin-like growth factor I oligonucleotide. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 10203
29. Cazenave C., Stein C.A., Loreau N., et al. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. Nucleic Acids Res. 17 (1989) 4255
30. Cha X.Y., Xu H., Ni Q., et al. Opioid peptide receptor studies. 4. Antisense oligodeoxynucleotide to the δ-opiod receptor delineates opiod receptor subtypes. Regul. Pept. 59 (1995) 247
31. Cheng Y.-C., Gao W., and Han F. Against human immunodeficiency virus and herpes viruses. Nucleosides Nucleotides 10 (1991) 155
32. Chiang M.Y., Chan H., Zounes M.A., et al. Antisense oligonucleotides inhibit ICAM-1 expression by two distinct mechanisms. J. Biol. Chem. 266 (1991) 18162
33. Chiasson B.J., Hooper M.L., Murphy P.R., et al. Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. Eur. J. Pharmacol. 227 (1992) 451
34. Chrissey L.A., Walz S.E., Pazirandeh M., et al. Internalization of oligodeoxyribonucleotides by Vibrio parahaemolyticus. Antisense Res. Dev. 3 (1993) 367
35. Cohen J.S. Phosphorothioate oligodeoxynucleotides. In: Crooke S.T., and Lebleu B. (Eds). Antisense Research and Applications (1993), CRC Press, Boca Raton, Florida. 205
36. Colby C. The induction of interferon by natural and synthetic polynucleotides. Prog. Nucleic Acid Res. Mol. Biol. 11 (1971) 1
37. Cook P.D. Medicinal chemistry strategies for antisense research. In: Crooke S.T., and Lebleu B. (Eds). Antisense Research and Applications (1993), CRC Press, Boca Raton, Florida. 303
38. Cornish K.G., Iversen P., Smith L., et al. Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol. Commun. 3 (1993) 239
39. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267 (1993) 1181
40. 14C labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269 (1994) 89
41. Cowsert L.M. Antiviral activities of oligonucleotides. In: Crooke S.T., and Lebleu B. (Eds). Antisense Research and Applications (1993), CRC Press, Boca Raton, Florida. 521
42. 2 mRNA of papillomavirus: Potential treatment of genital warts. Antimicrob. Agents Chemother. 37 (1993) 171
43. Crooke R.M. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti-Cancer Drug Des. 6 (1991) 609
44. Crooke R.M. Cellular uptake, distribution and metabolism of phosphorothioate, phosphorodiester and methylphosphonate oligonucleotides. In: Crooke S.T., and Lebleu B. (Eds). Antisense Research and Applications (1993), CRC Press, Boca Raton, Florida. 427
45. Crooke R.M. In vitro and in vivo toxicology of first generation analogs. In: Crooke S.T., and Lebleu B. (Eds). Antisense Research and Applications (1993), CRC Press, Boca Raton, Florida. 471
46. Crooke R.M., Graham M.J., Cooke M.E., et al. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J. Pharmacol. Toxicol. 275 (1995) 462
47. Crooke R.M., Crooke S.T., Graham M.J., et al. Effect of antisense oligonucleotides on cytokine release from human keratinocytes in an in vitro model of skin. Toxicol. Appl. Pharmacol. 140 (1996) 85-93
48. Crooke S.T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32 (1992) 329
49. Crooke S.T. Progress toward oligonucleotide therapeutics: Pharmacodynamic properties. FASEB J. 7 (1993) 533
50. Crooke S.T. Oligonucleotide therapeutics. In: Wolff M.E. (Ed). Burger's Medicinal Chemistry and Drug Discovery. 5th Ed. 1 (1995), Wiley, New York 863
51. Crooke S.T. "Therapeutic Applications of Oligonucleotides." (1995), R.G. Landes Co., Austin, Texas.
52. In: Crooke S.T., and Lebleu B. (Eds). "Antisense Research and Applications." (1993), CRC Press, Boca Raton, Florida.
53. 14C labeled afovirsen sodium in genital wart patients. J. Pharmacol. Exp. Ther. 56 (1994) 641
54. Crooke S.T., Lemonidis K.M., Neilson L., et al. Kinetic characteristics of E. coli RNase H1: Cleavage of various antisense oligonucleotide-RNA duplexes. Biochem. J. 312 (1995) 599
55. Crooke S.T., Graham M.J., Zuckerman J.E., et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277 2 (1996) 923-937
56. Crouch R.J., and Dirksen M.-L. Ribonucleases H. In: Linn S.M., and Roberts R.J. (Eds). Nucleases (1985), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 211
57. Crum C., Johnson J.D., Nelson A., et al. Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translation in vitro. Nucleic Acid Res. 16 (1988) 4569
58. Dean N.M., and McKay R. Inhibition of PKC-α expression in mice after systemic administration of phosphorothioate antisense oligonucleotides. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 11762
59. Dean N.M., McKay R., Miraglia L., et al. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of PKC-α expression. Cancer Res. 56 (1996) 3499-3507
60. DeClercq E., Eckstein F., and Merigan T.C. Interferon induction increased through chemical modification of a synthetic polyribonucleotide. Science 165 (1969) 1137
61. DeMesmaeker A., Haner R., Martin P., et al. Antisense oligonucleotides. Acc. Chem. Res. 28 (1995) 366
62. Desjardins J., Mata J., Brown T., et al. Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo. J. Drug Target. 2 (1995) 477
63. Dominski Z., and Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 673
64. Doris-Keller H. Site specific enzymatic cleavage of RNA. Nucleic Acids Res. 7 (1979) 179
65. Ecker D.J. Strategies for invasion of RNA secondary structure. In: Crooke S.T., and Lebleu B. (Eds). Antisense Research and Applications (1993), CRC Press, Boca Raton, Florida. 387
66. Ecker D.J., Vickers T.A., Bruice T.W., et al. Pseudo-half knot formation with RNA. Science 257 (1992) 958
67. Eder P.S., and Walder J.A. Ribonuclease H from K562 human erythroleukemia cells. J. Biol. Chem. 206 (1991) 6472
68. Flanagan L.M., McCarthy M.M., Brooks P.J., Pfaff D.W., and McEwen B.S. Arginine vasopressin levels after daily infusions of antisense oligonucleotides into the supraoptic nucleus. Ann. N. Y. Acad. Sci. 689 (1993) 520
69. Freier S.M. Hybridization: Considerations affecting antisense drugs. In: Crooke S.T., and Lebleu B. (Eds). Antisense Research and Applications (1993), CRC Press, Boca Raton, Florida. 67
70. Furdon P., Dominski Z., and Kole R. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res. 17 (1989) 9193
71. Gagnor C., Bertrand J., Thenet S., et al. α-DNA. VI: Comparative study of α-and β-anomeric oligodeoxyribonucleotides in hybridization to mRNA and in cell free translation inhibition. Nucleic Acids Res. 15 (1987) 10419
72. Gagnor C., Rayner B., Leonetti J.-P., et al. α-DNA. IX. Parallel annealing of α-anomeric oligodeoxyribonucleotides to natural mRNA is required for interference in RNase H mediated hydrolysis and reverse transcription. Nucleic Acids Res. 17 (1989) 5107
73. Galbraith W.M., Hobson W.C., Giclas P.C., et al. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4 (1994) 201
74. Gao W., Stein C.A., Cohen J.S., et al. Effect of phosphorothioate homooligodeoxynucleotides on herpes simplex virus type 2-induced DNA polymerase. J. Biol. Chem. 264 (1989) 11521
75. Gao W.-Y., Han F.-S., Storm C., et al. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology. Mol. Pharmacol. 41 (1991) 223
76. Giles R.V., and Tidd D.M. Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage of RNase H using chimeric methylphosphorodiester structures. Nucleic Acids Res. 20 (1992) 763
77. Giles R.V., Spiller D.G., and Tidd D.M. Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Dev. 5 (1995) 23
78. Gillardon F., Beck H., Uhlmann E., et al. Inhibition of c-fos protein expression in rat spinal cord by antisense oligodeoxynucleotide superfusion. Eur. J. Neurosci. 6 (1994) 880
79. Gillespie D., and Spiegelman S. A quantitative assay for DNA-RNA hybrids with DNA immobilized on a membrane. J. Mol. Biol. 12 (1965) 829-842
80. Glover J.M., Leeds J.M., and Mant T.G.K. Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligonucleotide (ISIS 2302). J. Pharmacol. Exp. Ther. (1997) In press.
81. Goodchild J., Agrawal S., Civeira M.P., et al. Inhibition of human immunodeficiency virus replication by antisense oligonucleotides. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 5507
82. Graham M.J., Freier S.M., Crooke R.M., et al. Tritium labeling of antisense oligonucleotides by exchange with tritiated water. Nucleic Acids Res. 21 (1993) 3737
83. Gutierrez A.J., Terhorst T.J., Matteucci M.D., et al. 5-Heteroaryl-2-deoxyuridine analogs. Synthesis and incorporation into high-affinity oligonucleotides. J. Am. Chem. Soc. 116 (1994) 5540
84. 1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul. Pept. 49 (1993) 167
85. Haeuptle M.T., Frank R., and Dobberstein B. Translation arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length. Nucleic Acids Res. 14 (1986) 1427
86. 6A). Biochem. Biophys. Res. Commun. 50 (1973) 1104
87. Hall J., Husken D., Pieles U., et al. Efficient sequence-specific cleavage of RNA using novel europium complexes conjugated to oligonucleotides. Chem. Biol. 1 (1994) 185
88. Hanvey J.C., Peffer N.J., Bisi J.E., et al. Antisense and antigene properties of peptide nucleic acids. Science 258 (1992) 1481
89. Heikkila R., Schwab G., and Wickström E. A c-myc antisense oligonucleotide inhibits entry into S phase but not progress from G0 to G1. Nature (London) 328 (1987) 445
90. Heilig M., Engel J.A., and Soderpalm B. c-fos antisense in the nucleus accumbens blocks the locomotor stimulant action of cocaine. Eur. J. Pharmacol. 236 (1993) 339
91. Helene C., and Toulme J.J. Control of gene expression by oligonucleotides covalently linked to intercalating agents and nucleic acid-cleaving reagents. In: Cohen J.S. (Ed). Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression (1989), CRC Press, Boca Raton, Florida. 137
92. Henry S.P., Orr J.L., Bruner R.H., et al. Comparison of the toxicities profile of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology 116 1-3 (1997) 77-88
93. Henry S.P., Taylor J., Midgley L., et al. Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide. 1. 4-week study in CD-I mice. Antisense Nucleic Drug Dev. (1997) In press
94. Henry S.P., Bolte H., Auletta C., et al. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide. 2. 4-week study in cynomolgus monkeys. Toxicology (1997) In press
95. Henry S.P., Giclas P., Leeds J., et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J. Pharmacol. Exp. Ther. (1997) In press
96. S.P. Henry, W. Novotny, J. Leeds, (1997e). Inhibition of clotting parameters by a phosphorothioate oligonucleotide. In preparation.
97. Henry S.P., Zuckerman J.E., Rojko J., et al. Toxicologic properties of several novel oligonucleotide analogs in mice. Anti-cancer Drug Des. 12 1 (1997) 1-14
98. Hertl M., Neckers L.M., and Katz S.I. Inhibition of interferon-γ-induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects. J. Invest. Dermatol. 104 (1995) 813
99. Higgins K.A., Perez J.R., Coleman T.A., et al. Antisense inhibition of the p65 subunit of NF-B blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 9901
100. Hijiya N., Zhang J., Ratajczak M.Z., et al. Biological and therapeutic significance of MYB expression in human melanoma. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4499
101. Hodges D., and Crooke S.T. Inhibition of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides. Mol. Pharmacol. 48 (1995) 905
102. Hoke G.D., Draper K., Freier S.M., et al. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res. 19 (1991) 5743
103. Hooper M.L., Chiasson B.J., and Robertson H.A. Infusion into the brain of an antisense oligonucleotide to the immediate-early gene c-fos suppresses production of fos and produces a behavioral effect. Neuroscience 63 (1994) 917
104. Hughes J.A., Avrutskaya A.V., Brouwer K.L.R., et al. Radiolabeling of methylphosphonate and phosphorothioate oligonucleotides and evaluation of their transport in everted rat jejunum sacs. Pharmacol. Res. 12 (1995) 817
105. Hutcherson S.L., Palestine A.G., Cantrill H.L., et al. Antisense oligonucleotide safety and efficacy for CMV retinitis in AIDS patients. Int. Conf. Antimicroh. Agents Chemother., 35th (1995) 204
106. Inoue H., and Ohtsuka E. Synthesis and hybridization of dodecadeoxyribonucleotides containing a fluorescent pyridopyrimidine deoxynucleoside. Nucleic Acids Res. 13 (1985) 7119
107. Iversen P. In vivo studies with phosphorothioate oligonucleotides: Pharamcokinetic prologue. Anti-Cancer Drug Des. 6 (1991) 531
108. Joos R.W., and Hall W.H. Determination of binding constants of serum albumin for penicillin. J. Pharmacol. Exp. Ther. 166 (1969) 113
109. Kawasaki A.M., Casper M.D., Freier S.M., et al. Uniformly modified 2-deoxy-2-fluoro phosphorothioate oligonucleotides as nuclease resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36 (1993) 831
110. Kindy M.S. NMDA receptor inhibition using antisense oligonucleotides prevents delayed neuronal death in gerbil hippocampus following cerebral ischemia. Neurosci. Res. Commun. 14 (1994) 175
111. Kitajima I., Shinohara T., Bilakovics J., et al. Ablation of transplanted HTLV-1 tax-transformed tumors in mice by antisense inhibition of NF-B. Science 258 (1992) 1792
112. Konradi C., Cole R.L., Heckers S., et al. Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J. Neurosci. 14 (1994) 5623
113. Krieg A.M., Yi A.-K., and Matson S. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (London) 374 (1995) 546
114. Kulka M., Smith C., Aurelian L., et al. Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonates) complementary to the acceptor splice junction of herpes simplex virus type 1 immediately early mRNA. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 6868
115. Kuramoto E., Yano O., Kimura Y., et al. Oligonucleotide sequences required for natural killer cell activation. Jpn. J. Cancer Res. 83 (1992) 1128
116. 2-agonist antinociception. NeuroReport 5 (1994) 1049
117. Lamond A.I., and Sproat B.S. Antisense oligonucleotides made of 2-O-alkyl RNA: Their properties and applications in RNA biochemistry. FEBS Lett. 325 (1993) 123
118. Lemaitre M., Bayard B., and Lebleu B. Specific antiviral activity of a poly(l-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N-protein mRNA initiation site. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 648
119. 1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul. Pept. 59 (1995) 229
120. Lima W.F., Monia B.P., Ecker D.J., et al. Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry 31 (1992) 12055
121. Lin K.T.P., and Brown D.M. Synthesis and duplex stability of oligonucleotides containing cytosine-thymine analogues. Nucleic Acids Res. 17 (1989) 10373
122. Lin K.-Y., Jone R.J., and Matteucci M. Tricyclic-2-deoxycytidine analogs: Syntheses and incorporation into oligodeoxynucleotides which have enhanced binding to complementary RNA. J. Am. Chem. Soc. 117 (1995) 3873
123. Loke S.L., Stein C.A., Zhang X.H., et al. Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 3474
124. Maher III J.L., Wold B., and Dervan P.G. Inhibition of DNA binding properties by oligonucleotide-directed triple helix formation. Science 245 (1989) 725
125. Maier J.A.M., Voulalas P., Roeder D., et al. Extension of the life-span of human endothelial cells by an interleukin-1α antisense oligomer. Science 249 (1990) 1570
126. Majumdar C., Stein C.A., Cohen J.S., et al. Stepwise mechanism of HIV reverse transcriptase: Primer function of phosphorothioate oligodeoxynucleotide. Biochemistry 28 (1989) 1340
127. Mani S.K., Blaustein J.D., and Allen J.M.C. Inhibition of rat sexual behavior by antisense oligonucleotides to the progesterone receptor. Endocrinology (Baltimore) 135 (1994) 278
128. Manoharan M. Designer antisense oligonucleotides: Conjugation chemistry and functionality placement. In: Crooke S.T., and Lebleu B. (Eds). Antisense Research and Therapeutics (1993), CRC Press, Boca Raton, Florida. 303
129. Marcus-Sekura C.J., Woerner A.M., Shinozuka K., et al. Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages. Nucleic Acids Res. 15 (1987) 5749
130. Martin F.H., Castro M.M., Aboul-ela F., et al. Base pairing involving deoxyinosine: Implications for probe design. Nucleic Acids Res. 13 (1985) 8927
131. Martin P. New access to 2-O-alkylated ribonucleosides and properties of 2-O-alkylated oligoribonucleotides. Helv. Chitn. Acta 78 (1995) 486
132. Matsukura M., Shinozuka K., Zon G., et al. Phosphorothioate analogs of oligodeoxyribonucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7706
133. 67 mRNAs modulate reproductive behavior in the female rat. Brain Res. 636 (1994) 209
134. McCarthy M.M., Nielsen D.A., and Goldman D. Antisense oligonucleotide inhibition of tryptophan hydroxylase activity in mouse brain. Regul. Pept. 59 (1995) 163
135. McManaway M.E., Neckers L.M., Loke S.L., et al. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 335 (1990) 808
136. Messina J.P., Gilkeson G.S., and Pisetsky D.S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 147 (1991) 1759
137. Miller P.S. Non-ionic antisense oligonucleotides. In: Cohen J.S. (Ed). Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression (1989), CRC Press, Boca Raton, Florida. 79
138. Minshull J., and Hunt T. The use of single-stranded DNA and RNase H to promote quantitative hybrid arrest of translation of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Res. 14 (1986) 6433
139. Mirabelli C.K., and Crooke S.T. Antisense oligonucleotides in the context of modern molecular drug discovery and development. In: Crooke S.T., and Lebleu B. (Eds). Antisense Research and Applications (1993), CRC Press, Boca Raton, Florida. 7
140. Mirabelli C.K., Bennett C.F., Anderson K., et al. In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anti-Cancer Drug Des. 6 (1991) 647
141. Miyao T., Takakura Y., Akiyama T., et al. Stability and pharmacokinetic characteristics of oligonucleotides modified at terminal linkages in mice. Antisense Res. Dev. 5 (1995) 115
142. Mizoguchi H., Narita M., Nagase H., et al. Antisense oligodeoxynucleotide to a δ-opioid receptor blocks the antinociception induced by cold water swimming. Regul. Pept. 59 (1995) 255
143. Monia B.P., Johnston J.F., Ecker D.J., et al. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. 267 (1992) 19954
144. Monia B.P., Lesnik E.A., and Gonzalez C. Evaluation of 2-modified oligonucleotides containing 2-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268 (1993)
145. Monia B.P., Johnston J.F., Geiger T., et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nat. Med. 2 6 (1996) 668-675
146. Monia B.P., Johnston J.F., and Sasmor H. Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J. Biol. Chem. 271 24 (1996) 14533-14540
147. Morishita R., Gibbons G.H., Ellison K.E., et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 8474
148. 1 and CDC 2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 149 (1994) 13
149. Morvan F., Rayner B., and Imbach J.-L. α-Oligonucleotides: A unique class of modified chimeric nucleic acids. Anti-Cancer Drug Des. 6 (1991) 521
150. Nagel K.M., Holstad S.G., and Isenberg K.E. Oligonucleotide pharmacotherapy: An antigene strategy. Pharmacotherapy 13 (1993) 177
151. Neckers L.M. Cellular internalization of oligodeoxynucleotides. In: Crooke S.T., and Lebleu B. (Eds). Antisense Research and Applications (1993), CRC Press, Boca Raton, Florida. 451
152. Nesterova M., and Cho-Chung Y.S. A single injection protein kinase α-directed antisense treatment to inhibit tumor growth. Nat. Med. 1 (1995) 528
153. Neumann I., Porter D.W.F., Landgraf R., et al. Rapid effect on suckling of an oxytocin antisense oligonucleotide administered into rat supraoptc nucleus. Bull. Am. Phys. Soc. (1994) R852
154. Nikiforov T.T., and Connolly B.A. The synthesis of oligodeoxynucleotides containing 4-thiothymidine residues. Tetrahedron Lett. 32 (1991) 3851
155. Offensperger W.-B., Offensperger S., Walter E., et al. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J. 12 (1993) 1257
156. Ogo H., Hirai Y., Miki S., et al. Modulation of substance P/neurokinin-1 receptor in human astrocytoma cells by antisense oligodeoxynucleotides. Gen. Pharmacol. 25 (1994) 1131
157. Osen-Sand A., Catsicas M., and Staple J.K. Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo. Nature (London) 364 (1993) 445
158. Parmentier G., Schmitt G., Dolle F., et al. A convergent synthesis of 2-O-methyl uridine. Tetrahedron 50 (1994) 5361
159. Perlaky L., Saijo Y., Busch R.K., et al. Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. Anti-Cancer Drug Des. 8 (1993) 3
160. Phillips M.I., Wielbo D., and Gyurko R. Antisense inhibition of hypertension: A new strategy for renin-angiotensin candidate genes. Kidney Int. 46 (1994) 1554
161. Pitsch S., Krishnamurthy R., Bolli M., et al. Pyranosyl-RNA ("p-RNA"): Base-pairing selectivity and potential to replicate. Helv. Chim. Acta 78 (1995) 1621
162. Pollio G., Xue P., Zanisi M., et al. Antisense oligonucleotide blocks progesterone-induced lordosis behavior in ovariectomized rats. Mol. Brain Res. 19 (1993) 135
163. Psietsky D.S., and Reich C.F. Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 54 (1993) 101
164. 2 dopamine receptors. Mol. Pharmacol. 48 (1995) 730
165. Quartin R., Brakel C., and Wetmur J. Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates. Nucleic Acids Res. 17 (1989) 7253
166. Quattrone A., Papucci L., Schiavone, et al. Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids. Anti-Cancer Drug Des. 9 (1994) 549
167. Rappaport J., Hanss B., Kopp J.B., et al. Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy. Kidney Int. 47 (1995) 1462
168. Ratajczak M.Z., Kant J.A., Luger S.M., et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 11823
169. Rosolen A., Whitesell L., Olegalo M., et al. Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line. Cancer Res. 50 (1990) 6316
170. 1) receptor antisense oligonucleotide attenuates thirst in the rat. Regul. Pept. 59 (1995) 183
171. 3H-labeled oligonucleotides. I. Comparion of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45 (1994) 932
172. 3H-labeled oligonucleotides. II. 3,5-Blocked oligonucleotides. Mol. Pharmacol. 47 (1995) 636
173. Sanghvi Y.S. Heterocyclic base modifications in nucleic acids and their applications in antisense oligonucleotides. In: Crooke S.T., and Lebleu B. (Eds). Antisense Research and Applications (1993), CRC Press, Boca Raton, Florida. 273
174. In: Sanghvi Y.S., and Cook P.D. (Eds). "Carbohydrate Modifications in Antisense Research." (1994), American Chemical Society, Washington, D.C.
175. Sanghvi Y.S., Hoke G.D., Freier S.M., et al. Antisense oligonucleotides: Synthesis and biological evaluation of oligodeoxynucleotides containing modified pyrimidines. Nucleic Acids Res. 21 (1993) 3197
176. Santa Lucia J., Kierzek R., and Turner D.H. Functional group substitutions as probes of hydrogen bonding between GA mismatches in RNA internal loops. J. Am. Chem. Soc. 113 (1991) 4314
177. Sarin P.S., Agrawal S., and Civeira M.P. Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 7448
178. Saxena S.K., and Ackerman E.J. Microinjected oligonucleotides complementary to the α-sarcin loop of 28 S RNA abolish protein synthesis in Xenopus oocytes. J. Biol. Chem. 265 (1990) 3263
179. Sburlati A.R., Manrow R.E., and Berger S.L. Prothymosin a antisense oligomers inhibit myeloma cell division. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 253
180. Schwab G., Chavany C., Duroux I., et al. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 10460
181. 6-methylated 7-dazaadenine and 8-aza-7-deazaadenine: Solid phase synthesis of oligodeoxyribonucleotides and properties of self-complementary duplexes. Helv. Chim. Acta 72 (1989) 868
182. Seela F., Ramzaeva N., and Chen Y. Oligonucleotide duplex stability controlled by the 7-substituents of 7-deazaguanine bases. Bioorg. Med. Chem. Lett. 5 (1995) 3049
183. Simons M., Edelman E.R., and De Keyser J.-L. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (London) 359 (1992) 67
184. Simons M., Edelman E.R., and Rosenberg R.D. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J. Clin. Invest. 9 (1994) 2351
185. 1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4504
186. Skutella T., Probst J.C., Jirikowski G.F., et al. Ventral tegmental area (VTA) injections of tyrosine hydroxylase phosphorothioate antisense oligonucleotide suppress operant behavior in rats. Neurosci. Lett. 167 (1994) 55
187. Smith C.C., Aurelian L., Reddy M.P., et al. Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 2787
188. Sproat B.S., and Lamond A.I. 2-O-Alkyloligoribonucleotides. In: Crooke S.T., and Lebleu B. (Eds). Antisense Research and Applications (1993), CRC Press, Boca Raton, Florida. 351
189. Sproat B.S., Lamond A.L., Beijer B., et al. Highly efficient chemical synthesis of 2-0-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. Nucleic Acids Res. 17 (1989) 3373
190. Sproat B.S., Iribarren A.M., et al. New synthetic routes to synthons suitable for 2-O-aliyloligoribonucleotide assembly. Nucleic Acids Res. 19 (1991) 733
191. Srinivasan S.K., Tewary H.K., and Iversen P.L. Characterization of binding sites, extent of binding and drug interactions of oligonucleotides with albumin. Antisense Res. Dev. 5 (1995) 131
192. Stein C.A., and Cheng Y.-C. Antisense oligonucleotides as therapeutic agents. Is the bullet really magic?. Science 261 (1993) 1004
193. Stein C.A., and Cohen J.S. Phosphorothioate oligodeoxynucleotide analogues. In: Cohen J.S. (Ed). "Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression" (1989), CRC Press, Boca Raton, Florida. 97
194. Stein C.A., Neckers L.M., Nair B.C., et al. Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 with gpl20 to CD4. J. AIDS 4 (1991) 686
195. Stepkowski S.M., Tu Y., Condon T.P., et al. Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J. Immunol. 10 (1994) 5336
196. Suzuki S., Pilowsky P., and Minson J. c-fos antisense in rostral ventral medulla reduces arterial blood pressure. J. Physiol. (London) R1418 (1994)
197. Tao L.-F., Marz K.A., Wongwit W., et al. Uptake, intracellular distribution, and stability of oligodeoxynucleotide phosphorothioate by. Schistosoma mansoni. Antisense Res. Dev. 5 (1995) 123
198. Temsamani J., Tang J.-Y., Padmapriya A., et al. Pharmacokinetics, biodistribution and stability of capped oligodeoxynucleotide phosphorothioates in mice. Antisense Res. Dev. 3 (1993) 277
199. Thompson J.D., and Gillespie D. Current concepts in quantitative molecular hybridization. Clin. Biochem. 23 (1990) 261-266
200. Thuong N.T., Asseline U., and Monteney-Garestier T. Oligodeoxynucleotides covalently linked to intercalating and reactive substances: Synthesis, characterization and physicochemical studies. In: Cohen J.S. (Ed). Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression (1989), CRC Press, Boca Raton, Florida. 25
201. Tischmeyer W., Grimm R., Schicknick H., et al. Sequence-specific impairment of learning by c-jun antisense oligonucleotides. NeuroReport 5 (1994) 1501
202. Ts'o P.O.P., Miller P.S., and Greene J.J. Nucleic acid analogs with targeted delivery at chemotherapeutic agents. In: Cheng Y.C., Gox B., and Minkoff M. (Eds). Development of Target-Oriented Anticancer Drugs (1983), Raven Press, New York 189
203. Vasanthakumar G., and Ahmed N.K. Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates. Cancer Commun. 1 (1989) 225
204. Vickers T., Baker B.F., Cook P.D., et al. Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element. Nucleic Acids Res. 19 (1991) 3359
205. Vlassov V.V. Inhibition of tick-borne viral encephalitis expression using covalently linked oligonucleotide analogs Meet. Oligodeoxynucleotides Antisense Inhibitors Gene Express.: Ther. Implications, Rockville, Maryland 15 (1989)
206. Wagner R.W., Matteucci M.D., Lewis J.G., et al. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260 (1993) 1510
207. Wahlestedt C., Pich E.M., Koob G.F., et al. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259 (1993) 528
208. Walder R.Y., and Walder J.A. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 5011
209. Walker K., Elela S.A., and Nazar R.N. Inhibition of protein synthesis by anti-5.8S rRNA oligodeoxyribonucleotides. J. Biol. Chem. 265 (1990) 2428
210. Wang S., Lee R.J., Cauchon G., et al. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 3318
211. Watson J.D., and Crick F.H.C. Molecular structure of nucleic acids: A structure for deoxyribose nucleic acid. Nature (London) 171 (1953) 737
212. 2 messenger RNA. Neuroscience 55 (1993) 607
213. Westerman P., Gross B., and Hoinkis G. Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides. Biomed. Biochem. Acta 48 (1989) 85
214. Whitesell L., Rosolen A., and Neckers L.M. In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide. Antisense Res. Dev. 1 (1991) 343
215. Wickström E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods 13 (1986) 97
216. Wickström E.L., Bacon T.A., Gonzalez A., et al. Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells in vitro. Cell Dev. Biol. 25 (1989) 297
217. Woodburn V.L., Hunter J.C., Durieux C., Poat J.A., and Hughes J. The effect of c-fos antisense in the formalin-paw test. Regul. Pept. 54 (1994) 327
218. Wyatt J.R., Vickers T.A., Roberson J.L., et al. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 1356
219. Zamecnik P.C., and Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 280
220. Zamecnik P.C., Goodchild J., Taguchi Y., et al. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 4143
221. Zerial A., Thuong N.T., and Helene C. Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent. Nucleic Acids Res. 15 (1987) 9909
222. 2 receptors: Behavioral correlates. Neurosci. Lett. 161 223 (1993) 4947
223. Zhang R., Yan J., Shahinian H., et al. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. 58 (1995) 44
224. Zhang R., Lu Z., Zhang X., et al. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clin. Chem. (Winston-Salem, N.C.) 41 (1995) 836
225. 1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 271 (1994) 1462
226. Zhang Z., Tang J.X., and Tang J.Y. Syntheses and properties of novel thiono triester modified antisense oligodeoxynucleotide phosphorothioates. Bioorg. Med. Chem. Lett. 5 (1995) 1735
227. Zheng H., Sahai B.M., Kilgannon P., et al. Specific inhibition of cell-surface T-cell receptor expression by antisense oligodeoxynucleotides and its effect on the production of an antigen-specific regulatory T-cell factor. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 3758
228. 2 dopamine receptors in mouse striatum. J. Pharmacol. Exp. Ther. 268 (1994) 1015